Alex A. Adjei

Dr. Adjei currently is the Professor of Oncology and a leader in clinical trials at the national renewal institute of Mayo Clinic (Rochester, Minnesota) with more scientific and clinical focus and duty. He is one of the top national renewal scientists and clinicians at the interface of translational and clinical cancer research, treatment and patient care. Previously, Dr. Ajei was the Professor and Chair, Department of Medicine, and Senior Vice-President for Clinical Research and Katherine Anne Gioia Chair of Cancer Medicine at Roswell Park Cancer Institute in Buffalo, NY, USA. Dr. Adjei completed an internal medicine residency at Howard University in Washington DC, and a medical oncology fellowship at Johns Hopkins University. He has been a Professor of Oncology at the Mayo Clinic College of Medicine, as well as a Consultant in Oncology at the Mayo Clinic and Foundation. He was the Director of the Phase I and Lung Cancer Programs at the Mayo Clinic Cancer Center. He has served on a number of National Institute's of Health Committees and is currently on the Clinical Research Review Committee Study Section of the National Center for Research Resources. He also co-chairs the Task Force on Clinical Trials Design for the Investigational Drugs Steering Committee at NCI. He is the Senior Editor of Molecular Cancer Therapeutics, and Associate Editor of Current Drug Targets, American Journal of Clinical Oncology and Investigational New Drugs. He is a program committee member of the American Society of Clinical Oncology (ASCO). He was a member of the Scientific Organizing Committee of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston in 2003 and has been on the AACR Annual Meeting Program Committee since 2002. He currently serves as faculty and a member of the program committee of the AACR-ASCO Methods in Clinical Research Workshop for fellows and junior faculty in Vail, Colorado. He was a member of the AACR Scientific Awards Committee in 2003 and 2005. Dr. Adjei's research is focused on development of novel agents for the therapy of solid tumors. In the clinic, his work has focused on the assessment of toxicity, pharmacology, and initial activity of selected agents and regimens in early clinical trials, development of biomarkers of drug effect, as well as phase II clinical trials of novel agents in cancer. He is interested in both the elucidation and research of mechanisms of action and resistance of novel agents that inhibit cell signaling.